Current Status and Future Perspectives of Endocrine Therapy for Breast Cancer: From Classical Approaches to the Evolution of Precision Systemic Medicine

Hang Lei and Lu Gan
Additional contact information
Hang Lei: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Lu Gan: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Current Research in Medical Sciences, 2026, vol. 5, issue 2, 55-60

Abstract: Hormone receptor-positive breast cancer is the most prevalent molecular subtype of breast cancer. Its therapeutic strategy has progressively evolved from simple endocrine deprivation toward a systematic management model centered on endocrine therapy and integrated with molecularly targeted treatment and dynamic monitoring. This review summarizes the developmental trajectory of endocrine therapy for breast cancer, outlines the classical therapeutic agents and combination strategies used after endocrine resistance, and discusses future directions driven by liquid biopsy, artificial intelligence, and emerging estrogen receptor degradation technologies.

Keywords: breast cancer; endocrine therapy; CDK4/6 inhibitors; resistance; liquid biopsy; precision medicine (search for similar items in EconPapers)
Date: 2026
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.paradigmpress.org/crms/article/view/2060/1919 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bdz:curmsc:v:5:y:2026:i:2:p:55-60

DOI: 10.63593/CRMS.2026.03.06

Access Statistics for this article

More articles in Current Research in Medical Sciences from Paradigm Academic Press
Bibliographic data for series maintained by Editorial Office ().